MUM2B Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Head-Neck cancer cell lines |
| Organism |
Human |
| Donor History |
Melanoma |
| Growth Properties |
Adherent |
| Growth Conditions |
Culture medium: RPMI 1640 ,w: 2.0 mM stable Glutamine ,w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Seeding density: 2-4*10^4/cm². Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
The MUM2B cell line is a metastatic uveal melanoma model derived from a hepatic metastasis of a uveal melanoma tumor. This cell line is extensively utilized in ocular oncology research to study the aggressive and invasive characteristics of metastatic uveal melanoma. Unlike primary uveal melanoma cell lines, MUM2B exhibits heightened metastatic behavior, making it a critical tool for understanding the progression and treatment resistance of advanced melanoma.
MUM2B cells have been shown to retain key melanoma markers such as S-100, HMB-45, and Melan-A, confirming their melanocytic origin. Additionally, this cell line is characterized by its ability to mimic vasculogenic patterns in vitro, a phenomenon associated with tumor aggressiveness and metastatic potential. MUM2B has been used to investigate the molecular mechanisms driving melanoma progression, including the role of apoptosis resistance pathways and mitochondrial dysfunction. The cell line responds to specific apoptotic inducers such as NOXA in a p53-independent manner, highlighting its utility in exploring therapeutic strategies targeting apoptosis-resistant tumors.
Research using MUM2B has contributed significantly to identifying potential therapeutic targets for metastatic melanoma. Studies demonstrate its sensitivity to innovative compounds such as γ-secretase inhibitors (GSI), which induce apoptosis selectively in melanoma cells while sparing normal melanocytes. These findings underscore MUM2B’s role as a vital model for testing novel therapeutic agents and improving the understanding of metastatic uveal melanoma biology.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

